COMPANY

Bioaxone Biosciences, Inc.

Profile checked Oct 10, 2026

Keywords: cerebral cavernous malformation Spinal Cord Injury Acute Cervical Spinal Cord Injury Cethrin (BA-210) Cethrin® (BA-210)

2Trials (company is sponsor)10NIH grants

Timeline

2015-07 Trial start Phase 2/Phase 3: Cethrin in Acute Cervical Spinal Cord Injury source ↗

Clinical trials (lead sponsor) 2

Record	Title	Phase	Status	Start	Primary completion
NCT02053883	Cethrin in Acute Cervical Spinal Cord Injury	Phase 2/Phase 3	Withdrawn	2015-07	2016-05 (estimated)
NCT00610337	Safety and Efficacy of Cethrin® in Adult Subjects With Acute Cervical Spinal Cord Injury	Phase 2	Withdrawn	Not listed	Not listed

NIH awards 10

Annual award amounts. Total $6.1M.

Sep 21, 2018 NIH award 1R44NS110290-01 FY2018: $224,454 awarded for that fiscal year; activity R44 (SBIR); PI ROSEN, KENNETH M; recipient as written: BIOAXONE BIOSCIENCES, INC., Boston, MA. An oral ROCK2-selective inhibitor for t source ↗
Jun 25, 2018 NIH award 5R44NS084489-03 FY2018: $1,059,073 awarded for that fiscal year; activity R44 (SBIR); PI MCKERRACHER, LISA J; recipient as written: BIOAXONE BIOSCIENCES, INC., Boston, MA. Development of self-delivering RNA source ↗
Sep 13, 2017 NIH award 2R44NS084489-02 FY2017: $735,822 awarded for that fiscal year; activity R44 (SBIR); PI MCKERRACHER, LISA J; recipient as written: BIOAXONE BIOSCIENCES, INC., Boston, MA. Development of self-delivering RNAi source ↗
Aug 9, 2017 NIH award 5R44NS095420-03 FY2017: $1,576,432 awarded for that fiscal year; activity R44 (SBIR); PI MCKERRACHER, LISA J; recipient as written: BIOAXONE BIOSCIENCES, INC., Boston, MA. Development of BA-1049 for treatme source ↗
Sep 14, 2016 NIH award 4R44NS095420-02 FY2016: $1,430,655 awarded for that fiscal year; activity R44 (SBIR); PI MCKERRACHER, LISA J; recipient as written: BIOAXONE BIOSCIENCES, INC., Boston, MA. Development of BA-1049 for treatme source ↗
Jan 30, 2016 NIH award 1R44NS095420-01 FY2016: $280,625 awarded for that fiscal year; activity R44 (SBIR); PI MCKERRACHER, LISA J; recipient as written: BIOAXONE BIOSCIENCES, INC., Boston, MA. Development of BA-1049 for treatment source ↗
Feb 17, 2015 NIH award 1R43NS090664-01 FY2015: $319,201 awarded for that fiscal year; activity R43 (SBIR); PI MCKERRACHER, LISA J; recipient as written: BIOAXONE BIOSCIENCES, INC., Boston, MA. Combination of BA-210 and digestion source ↗
Sep 8, 2014 NIH award 3R43EY024163-01S1 FY2014: $25,000 awarded for that fiscal year; activity R43 (SBIR); PI MCKERRACHER, LISA J; recipient as written: BIOAXONE BIOSCIENCES, INC., Boston, MA. Regulatory development of PEGylate source ↗
Jul 30, 2014 NIH award 1R43NS084489-01A1 FY2014: $224,789 awarded for that fiscal year; activity R43 (SBIR); PI MCKERRACHER, LISA J; recipient as written: BIOAXONE BIOSCIENCES, INC., Boston, MA. Development of self-delivering RNA source ↗
Mar 20, 2014 NIH award 1R43EY024163-01 FY2014: $223,651 awarded for that fiscal year; activity R43 (SBIR); PI MCKERRACHER, LISA J; recipient as written: BIOAXONE BIOSCIENCES, INC., Boston, MA. Investigation of PEGylated BA-210 fo source ↗